293780 — AptaBio Therapeutics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for AptaBio Therapeutics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2019 December 31st	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-6,298	-3,919	-10,689	-10,565	-19,098
Depreciation
Amortisation
Non-Cash Items	101	-1,424	-90.1	1,715	3,258
Unusual Items
Purchased R&D
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	120	1,333	1,562	1,557	1,244
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-6,002	-3,785	-8,897	-6,833	-14,095
Capital Expenditures	-3,740	-2,076	-169	-1,186	-167
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-40,794	2,448	1,302	2,929	-12,570
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-44,534	371	1,133	1,743	-12,737
Financing Cash Flow Items	-3,567	39.5	-356	-5.24	-19.2
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	62,814	1,508	-376	496	49,854
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	12,290	-1,915	-8,120	-4,577	23,027